KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.